Simon Crass
Gastroenterology · Angola, INNPI 1336450766
Payments from drug & device makers
Across 172 payments — averaging $45.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Janssen Research & Development, LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Lilly USA, LLC$330
- Bristol Myers Squibb$202
- Pfizer$142
- plus $545 from 18 others
What the payments were for
- Consulting fees$1,80030%
- Food & beverage$4,24270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 87 | $3,814 |
| Janssen Research & Development, LLC | 7 | $1,821 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $1,009 |
| Lilly USA, LLC | 7 | $330 |
| Bristol Myers Squibb | 7 | $202 |
| Pfizer | 8 | $142 |
| Regeneron Healthcare Solutions, Inc. | 3 | $101 |
| Gilead | 3 | $69 |
| Johnson & Johnson | 4 | $57 |
| Ironwood Pharmaceuticals, Inc | 2 | $36 |
| Pharming Healthcare, Inc. | 1 | $35 |
| Medtronic | 1 | $34 |
| Madrigal Pharmaceuticals | 1 | $31 |
| Janssen Scientific Affairs, LLC | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Alfasigma USA, Inc. | 1 | $19 |
| QOL Medical, LLC | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Sanofi | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Intercept Pharmaceuticals, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Ardelyx, Inc. | 1 | $14 |
| Echosens North America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,863 in reported general payments places this provider in the 70th percentile of 323 gastroenterology providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 22 | $586,512 |
| Mesalamine | 17 | $6,753 |
| Esomeprazole Magnesium | 16 | $584 |
| Omeprazole | 27 | $368 |
| MethotrexateMethotrexate Sodium | 11 | $70 |
| Ondansetron OdtOndansetron | 21 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $57 | $586,51222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 323 gastroenterology providers in Indiana.
Other gastroenterology in Angola
- Nelson MoyAngola$12K
- Monika FischerIndianapolis$2.8M
- Douglas RexIndianapolis$2.3M
- Pankaj PatelSouth Bend$2.3M
- David PoundIndianapolis$1.4M
- Naga ChalasaniIndianapolis$1.1M
- Sashidhar SagiWestfield$1.1M
- Jonathan ObertNew Albany$758K
- David DresnerNew Albany$544K
- Marwan GhabrilIndianapolis$464K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.